SCHEMBL426569

SCHEMBL426569

COc1ccc(NC(=O)CCCl)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
MAPT P10636 2/20 0.55
HPGD P15428 2/20 0.55
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
TSHR P16473 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
RAB9A P51151 1/20 0.52
HTT P42858 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
LMNA P02545 2/20 0.51
THRB P10828 1/20 0.51
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30293239 1.00 ALDH1A1 (0.55) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL17536233 0.88 ALDH1A1 (0.67) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL430528 0.84 TP53 (0.60) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL11723848 0.83 ALDH1A1 (0.47) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL13368241 0.83 ALDH1A1 (0.59) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL28817127 0.82 ALDH1A1 (0.60) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL15145872 0.82 ALDH1A1 (0.56) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL28713814 0.82 ALDH1A1 (0.60) ALDH1A1MAPTHPGDKDM4EGAA
SCHEMBL6691041 0.80 L3MBTL1 (0.57) ALDH1A1MAPTKDM4EGAARAB9A
SCHEMBL6371005 0.79 RAB9A (0.75) ALDH1A1MAPTKDM4EGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109988093-B Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine 广东东阳光药业有限公司 2023-04-07 CN disclosed
US-8609847-B2 Dihydroquinolinone derivatives TAISHO PHARMACEUTICAL CO., LTD (JP) 2013-12-17 US disclosed
EP-2393802-B1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO LTD (JP) 2013-05-08 EP disclosed
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-26 US disclosed
EP-2393802-A1 DIHYDROQUINOLINONE DERIVATIVES Taisho Pharmaceutical Co., Ltd. (JP) 2011-12-14 EP disclosed
WO-2010090347-A1 DIHYDROQUINOLINONE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD. (JP) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022064-A1 DIHYDROQUINOLINONE DERIVATIVES PER2, CRY1, BACE1 ALDH1A1 464/4885MAPT 133/4885HPGD 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.